Connection

SRDAN VERSTOVSEK to Bone Marrow Cells

This is a "connection" page, showing publications SRDAN VERSTOVSEK has written about Bone Marrow Cells.
Connection Strength

0.388
  1. Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes. PLoS One. 2019; 14(9):e0222912.
    View in: PubMed
    Score: 0.126
  2. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res. 2011 Jun 01; 71(11):3831-40.
    View in: PubMed
    Score: 0.070
  3. Aberrant myeloid maturation identified by flow cytometry in primary myelofibrosis. Am J Clin Pathol. 2010 Feb; 133(2):314-20.
    View in: PubMed
    Score: 0.064
  4. Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia. Leuk Res. 2004 Jul; 28(7):707-11.
    View in: PubMed
    Score: 0.044
  5. High expression of the receptor tyrosine kinase Tie-1 in acute myeloid leukemia and myelodysplastic syndrome. Leuk Lymphoma. 2001 Jul; 42(3):511-6.
    View in: PubMed
    Score: 0.035
  6. Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies. Haematologica. 2016 06; 101(6):660-71.
    View in: PubMed
    Score: 0.025
  7. Treatment of systemic mastocytosis with denileukin diftitox. Am J Hematol. 2007 Dec; 82(12):1124.
    View in: PubMed
    Score: 0.014
  8. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 2003 Aug 01; 102(3):795-801.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.